Zacks Investment Research
06 Apr 2026, 14:40 UTC · 24w ago
Verdict
Headline takes no side. We score AURA +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 87% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
The Zacks Consensus Estimate for Aura Biosciences (AURA) full-year earnings has increased by 12.7% over the past quarter.
More positive than 78% of claims this week
Aura Biosciences (AURA) currently holds a Zacks Rank of #2 (Buy).
So whatA 'Buy' rank from a major research provider suggests a positive outlook for market outperformance over the next 1-3 months.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 64% of claims this week
Biodesix, Inc. (BDSX) has gained 121.6% year-to-date and holds a Zacks Rank of #2 (Buy).
More positive than 52% of claims this week
The Medical sector has returned an average of -3.7% year-to-date.
More negative than 64% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
The company has a Zacks Rank of #2 (Buy), positive earnings estimate revisions, and is significantly outperforming its sector year-to-date.
More positive than 87% of ticker scores this week
The company is up 121.6% year-to-date, has positive EPS estimate revisions, and holds a Zacks Rank of #2 (Buy).
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
−6.0%
Price is moving against the score
$6.15 vs $6.54 close before publication (Apr 2) · not market-adjusted
AURA chart →
